Combination therapy

Dabrafenib mesylate in combination with trametinib dimethyl sulfoxide is used to treat cancer patients with a certain BRAF gene mutation, such as: Treating undifferentiated thyroid cancer that is locally advanced or has spread to other parts of the body and cannot be treated locally, low-grade glioma, melanoma, metastasized non-small cell lung cancer in children 1 year and older who require systemic treatment, and for adults and children 6 years and older who cannot be removed surgically or have spread to other parts of the body, A solid tumor that worsens after other treatments and cannot be treated with other therapies.

Mechanism of action of Dabrafenib mesylate

Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.

Use of Dabrafenib Mesylate

Dabrafenib comes as a capsule to take by mouth and as a tablet to suspend in water and take by mouth. It is usually taken twice a day on an empty stomach, 1 hour before or 2 hours after a meal. Take dabrafenib about 12 hours apart at around the same times every day.   

Side effects of Dabrafenib Mesylate

Dabrafenib may cause headache;joint, muscle, or back pain;nausea;diarrhea;constipation;loss of appetite;cough, runny nose, or sore throat;hair loss;tiredness;thickening of the skin;infection of the skin around the fingernails or toenails;numbness and tingling of the arms, hands, legs, or feet;dry skin et.al.